Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The portfolio is made up of well-established injectable coagulants sold in Europe under various brand names, including Arixtra, Fraxiparine, Mon-Embolex and Orgaran.
Shares of Akcea Therapeutics were up more than 58% in premarket trading after its majority owner Ionis Pharmaceuticals announced it will acquire all outstanding shares of the company, which amounts to about 24% of available stock for $18.50 per share.
Jayson Dallas, president and chief executive officer of Aimmune, said the agreement with Nestlé recognizes the value of Aimmune’s longtime commitment to advancing therapies for food allergies.
The acquisition is expected to bolster ACADIA’s clinical pipeline to include non-opioid pain therapies that have potential non-addictive properties and reduced side effects typically seen with current opioid treatments.
They will operate after the deal as Yumanity Therapeutics, and will focus on protein misfolding and neurodegenerative diseases.
Pharmaceutical industry investors are betting on contract development and manufacturing organizations (CDMOs) this year, as they shift their focus from contract research organizations (CRO).
J&J said the acquisition will allow its subsidiary, Janssen Pharmaceutical, to broaden its leadership in immune-mediated diseases and drive further growth through expansion into autoantibody-driven disease.
Under terms of the deal, Sanofi will acquire all of the outstanding shares of Principia for $100 per share in cash, which represents an aggregate equity value of approximately $3.68 billion.
Less than one month after GlaxoSmithKline took a 10% stake in CureVac, the Germany-based company raised $213 million in an initial public offering Thursday.
Pfenex’ proprietary protein production platform, Pfenex Expression Technology, is used to improve existing treatments and create novel therapies.